次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

前立腺がん治療薬・治療機器の世界市場2015-2025年

THE PROSTATE CANCER THERAPEUTICS MARKET FORECAST 2015-2025
Opportunities For Leading Companies

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2015年8月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email (※デジタル著作権管理/DRM設定有り)
当調査レポートは英文225ページになります。
商品コード:VGN441

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
前立腺がん治療薬・治療機器の世界市場規模は2015年に83億ドルに達すると推計されます。今後2025年にかけて新たな治療法の参入、患者人口や診断率の増加などを背景に同市場は顕著な拡大が予測されます。
当レポートでは、2015年から2025年に至る前立腺がん治療薬および治療機器の世界市場予測、主要治療薬売上予測(Zytiga、Xtandi、Xofigo、Lupronなど全9製品)、治療機器タイプ別市場(近接照射療法、根治的前立腺切除術、外部ビーム放射線療法、凍結療法、HIFU)、主要国地域別市場などの詳細予測データを掲載しています。また研究開発パイプライン、リーディング企業詳細動向などの調査情報も盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】VGN441_thumbnail Prostate Cancer.jpg
◆前立腺がん治療薬・治療機器の世界市場予測2015-25年

◆治療薬・主要9製品、製品別売上予測2015-25および分析
(※以下を含む全9製品予測を掲載)
・Zytiga
・Xtandi
・Xofigo
・Lupron
・Zoladex
・Taxotere
・Provenge

◆治療機器・タイプ別市場予測2015-25年、および分析
・近接照射療法
・根治的前立腺切除術
・外部ビーム放射線療法
・凍結療法
・HIFU(高密度焦点式超音波治療法)

◆主要国・地域別市場予測2015-2025、および分析
・米国
・ドイツ、フランス、イタリア、スペイン、英国
・日本
・韓国
・インド
・中国
・ロシア
・メキシコ
・その他地域(Rest of the World)

◆研究開発パイプライン
・免疫療法
・遺伝子治療
・アンドロゲン受容体アンタゴニスト

◆リーディング企業7社動向、業績、研究開発、新製品、提携、展望など
・Johnson & Johnson
・AstraZeneca
・Varian Medical Systems
・Elekta
・Sanofi
・AbbVie
・Theragenics

◆専門家オピニオンインタビュー:
・Dr Katarzyna Nej-Wolosiak, Medical Science Lead, SOTIO

◆調査結論
(全225ページ、192個のデータ表・グラフ類)

visiongain is a trading partner with the US Federal Government
【レポート詳細目次、データ項目一覧(List of Tables)は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

THE PROSTATE CANCER THERAPEUTICS MARKET FORECAST 2015-2025

Table of Contents

1. Report Overview

1.1 The Prostate Cancer Therapeutics Market Overview
1.2 Prostate Cancer Therapeutics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction to Cancer

2.1 What is Cancer?
2.2 Phenotypic Characteristics of Cancer Cells
2.2.1 Uncontrollable Growth
2.2.2 Loss of Functioning Apoptotic Pathways
2.2.3 Lack of Differentiation
2.2.4 Increased Angiogenesis
2.2.5 Potential for Metastasis
2.2.6 Genetic Instability
2.3 What Causes Cancer?
2.4 Worldwide Prevalence of Cancer: A Global Picture
2.5 What is Prostate Cancer?
2.6 Worldwide Prevalence of Prostate Cancer: Rapid Global Growth
2.7 Risk Factors in Prostate Cancer
2.8 How is Prostate Cancer Diagnosed?
2.8.1 PSA Testing
2.8.2 Digital Rectal Examination Testing
2.8.3 Prostate Cancer Screening: Does The Cost Justify The Means?
2.8.4 Alternative Tests Could Change Diagnostics
2.9 Treating Prostate Cancer
2.9.1 Localised Prostate Cancer: Surgery/Radiation is Most Preferred
2.9.1.1 Brachytherapy
2.9.1.2 Radical Prostatectomy
2.9.1.3 External Beam Radiation Therapy
2.9.1.4 Cryotherapy
2.9.1.5 High-Intensity Focussed Ultrasound (HIFU)
2.9.2 Advanced Local or Metastatic Prostate Cancer: Androgen Deprivation Therapy
2.9.3 Non-Metastatic CRPC: Ketoconazole and Anti-Androgens
2.9.4 Metastatic CRPC: Expanding the Standard Taxotere Treatment Paradigm
2.9.5 First Line Chemotherapy: Docetaxel is a Standard Treatment
2.9.6 Post Docetaxel Therapy: Five FDA Approved Drugs
2.9.7 Second Line Chemotherapy: Jevtana Approved in 2010

3. The Prostate Cancer Therapeutics Market 2015-2025

3.1 The Global Prostate Cancer Therapeutics Market, 2014
3.2 The Global Prostate Cancer Therapeutics Market Forecast, 2015-2025
3.3 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints, 2015-2025

4. The Prostate Cancer Drugs Market 2015-2025

4.1 The Prostate Cancer Drugs Market: Increasing Choice of Drugs will Mean Higher Competition
4.2 The Prostate Cancer Drugs Market, 2014
4.3 Leading Prostate Cancer Drugs: Market Forecast, 2015-2025
4.3.1 The Market Shares of Leading Prostate Cancer Drugs, 2015-2025
4.4 First Generation Chemotherapies
4.4.1 Taxotere (Sanofi)
4.4.1.1 Taxotere Sales, 2014
4.4.1.2 Taxotere Sales Forecast, 2015-2025
4.5 Second Generation Chemotherapies
4.5.1 Jevtana (Sanofi)
4.5.1.1 Jevtana Sales, 2014
4.5.1.2 Jevtana Sales Forecast, 2015-2025
4.6 First Generation Hormones
4.6.1 Casodex (AstraZeneca)
4.6.1.1 Casodex Sales, 2014
4.6.1.2 Casodex Sales Forecast, 2015-2025
4.6.2 Lupron (AbbVie)
4.6.2.1 Lupron Sales, 2014
4.6.2.2 Lupron Sales Forecast, 2015-2025
4.6.3 Zoladex (AstraZeneca)
4.6.3.1 Zoladex Sales, 2014
4.6.3.2 Zoladex Sales Forecast, 2015-2025
4.7 Second Generation Hormones
4.7.1 Zytiga (Johnson & Johnson)
4.7.1.1 Zytiga Sales, 2014
4.7.1.2 Zytiga Sales Forecast, 2015-2025
4.7.2 Xtandi (Medivation/ Astellas Pharma)
4.7.2.1 Xtandi Sales, 2014
4.7.2.2 Xtandi Sales Forecast, 2015-2025
4.8 Immunotherapies
4.8.1 Provenge (Dendreon Corporation)
4.8.1.1 Provenge Sales, 2014
4.8.1.2 Provenge Sales Forecasts, 2015-2025
4.9 Radiopharmaceuticals
4.9.1 Xofigo (Bayer)
4.9.1.1 Xofigo Sales, 2014
4.9.1.2 Xofigo Sales Forecast, 2015-2025
4.10 Other Drugs
4.11 Prostate Cancer Drugs Pipeline, 2015
4.11.1 Phase III Development
4.11.1.1 DCVax-Prostate (NorthWest Biotherapeutics)
4.11.1.2 Tookad Soluble (Steba Biotech)
4.11.1.3 ProstAtak (Advantagene)
4.11.1.4 ARN-509 (Johnson & Johnson)
4.11.1.5 Custirsen (Oncogenex)
4.11.1.6 Prostvac (Bavarian Nordic)
4.11.2 Failed Phase III Drugs
4.11.2.1 Cabozantinib (Elexis)
4.11.2.2 Yervoy (Bristol Myers Squibb)
4.11.2.3 Tasquinimod (Active biotech AB/Ipsen)
4.11.2.4 Orteronel (Millenium Pharmaceuticals)
4.11.3 Phase II development
4.11.3.1 GDC-0980 (Roche)
4.11.3.2 GDC-0068 (Roche)
4.11.3.3 PSMA ADC (Progenics Pharmaceuticals)
4.11.3.4 Galeterone (Tokai Pharmaceuticals)
4.11.3.5 OGX-427 (OncoGenex Pharmaceuticals)
4.11.3.6 Abituzumab (Dl7E6) (Merck)
4.11.4 Phase I
4.11.4.1 ASG-5ME (Agensys/Seattle Genetics)
4.11.4.2 EMD-525797 (EMD Serono)
4.11.4.3 MGAH22 (MacroGenics)
4.11.4.4 RG7450 (Roche)
4.11.4.5 BAY2010112 (Bayer Pharmaceuticals)
4.11.4.6 BX-201 (Bellicum Pharmaceuticals)
4.12 The Leading Companies in the Prostate Cancer Drugs Market, 2015
4.12.1 Johnson & Johnson
4.12.1.1 Sales and Performance Analysis, 2014
4.12.1.2 Pharmaceutical Segment Sales Analysis, 2014
4.12.1.3 Oncology Drugs Sales and Performance Analysis, 2014
4.12.1.4 Pharmaceutical Segment R&D Performance Analysis, 2014
4.12.1.5. Acquisition of Aragon Pharmaceuticals
4.12.2 AstraZeneca
4.12.2.1 Sales and Performance Analysis, 2014
4.12.2.2 Pharmaceutical Segment Sales & R&D Analysis by Segment, 2014
4.12.2.3 Oncology Drugs Sales and Performance Analysis, 2014
4.12.2.4 AstraZeneca Collaborates To Enhance Its Oncology Pipeline, 2014
4.12.3 Sanofi
4.12.3.1 Sales and Performance Analysis, 2014
4.12.3.2 Sales and Performance Analysis by Segment, 2014
4.12.3.3 Oncology Sales and Performance Analysis, 2014
4.12.3.4 R&D Performance Analysis, 2014
4.12.3.5 Oncology Pipeline Portfolio
4.12.4 AbbVie
4.12.4.1 Sales and Performance Analysis, 2014
4.12.4.2 R&D Performance Analysis, 2014
4.12.4.3 Humira: From “Firs-In-Class” to “Best-In-Class”, 2014
4.12.4.4 Oncology Portfolio Pipeline Products, 2014

5. The Prostate Cancer Devices Market 2015-2025

5.1 The Prostate Cancer Devices Market 2014
5.2 The Prostate Cancer Devices Market Forecast, 2015-2025
5.2.1 The Market Shares of Leading Prostate Cancer Devices Submarkets, 2015-2025
5.3 The Brachytherapy Market 2015-2025
5.4 The Radical Prostatectomy Market 2015-2025
5.4.1 Intuitive Surgical’s da Vinci Surgical System
5.5 The External Beam Radiation Therapy Market, 2015-2025
5.6 The HIFU Market, 2015-2025
5.7 The Cryotherapy Market, 2015-2025
5.8 Leading Companies in the Prostate Cancer Devices Market 2015-2025
5.8.1 Varian Medical Systems
5.8.1.1 Sales and Performance Analysis, 2014
5.8.1.2 Oncology Segment Sales Analysis, 2014
5.8.1.3 Sales Analysis by Region, 2014
5.8.1.4 R&D Performance Analysis, 2014
5.8.1.5 Key Oncology Products, 2014
5.8.1.6 Varian and Siemens Partnership: Shaping the Future of Cancer Care
5.8.2 Elekta
5.8.2.1 Sales and Performance Analysis, 2014
5.8.2.2 Sales and Performance Analysis by Region, 2014
5.8.2.3 Elekta and Philips Establish Research Consortium
5.8.2.4 Product Launch and Development, 2014
5.8.3 Theragenics Corporation (acquired by Juniper)
5.8.3.1 Theragenics Sales Performance Analysis, 2014
5.8.3.2 Theragenics Sales Performance by Operation, 2012
5.8.3.3 Sales and Performance Analysis by Business Unit, 2012
5.8.3.4 Mergers and Acquisitions
5.8.3.4.1 Juniper’s acquisition of Theragenics
5.8.3.4.2 Acquisition of Needle Tech Products
5.8.3.4.3 Acquisition of Galt Medical
5.8.3.4.4 Acquisition of CP Medical

6. The Leading National Markets 2015-2025

6.1 Regional Breakdown of the Prostate Cancer Therapeutics Market, 2014
6.2 The Prostate Cancer Therapeutics Market: Regional Forecast, 2015-2025
6.2.1 Market Shares Forecasts of Leading National Prostate Cancer Therapeutics Markets, 2015-2025
6.3 The US Prostate Cancer Therapeutics Market 2015-2025: Largest National Market
6.4 The European Prostate Cancer Therapeutics Market, 2014
6.4.1 The European Prostate Cancer Therapeutics Market, 2015-2025
6.4.1.1 The German Prostate Cancer Therapeutics Market, 2015-2025
6.4.1.2 The French Prostate Cancer Therapeutics Market, 2015-2025
6.4.1.3 The UK Prostate Cancer Therapeutics Market, 2015-2025
6.4.1.4 The Spanish Prostate Cancer Therapeutics Market, 2015-2025
6.4.1.5 The Italian Prostate Cancer Therapeutics Market, 2015-2025
6.5 The Japanese Prostate Cancer Therapeutics Market, 2015-2025
6.6 The Brazilian Prostate Cancer Therapeutics Market, 2015-2025
6.7 The Russian Prostate Cancer Therapeutics Market, 2015-2025
6.8 The Indian Prostate Cancer Therapeutics Market, 2015-2025
6.9 The Chinese Prostate Cancer Therapeutics Market, 2015-2025
6.10 The South Korean Prostate Cancer Therapeutics Market, 2015-2025
6.11 The Mexican Prostate Cancer Therapeutics Market, 2015-2025
6.12 The Rest of the World Prostate Cancer Therapeutics Market, 2015-2025

7. Qualitative Analysis of the Prostate Cancer Therapeutics Market 2015-2025

7.1 SWOT Analysis, 2015-2025
7.2 Strengths
7.2.1 Rapidly Expanding Ageing Population
7.2.2 A Number of Promising Drug Candidates
7.2.3 Successful Launches through Partnerships between Small/Big Pharma Companies
7.3 Weaknesses
7.3.1 Prostate Cancer Treatment is Expensive
7.3.2 The Chances of Failure Are Big
7.3.3 U.S Medical Excise Tax
7.4 Opportunities
7.4.1 Rising incidence of Cancer
7.4.2 Emerging Markets are Developing
7.5 Threats
7.5.1 Concerns about Efficacy and Toxicity of Drugs
7.5.2 Governments Decreasing Healthcare Spending
7.5.3 Increase in Generic Competition
7.6 Porter’s Five Force Analysis
7.6.1 Rivalry Among Competitors [High]
7.6.2 Threat of New Entrants [High]
7.6.3 Power of Suppliers [Low]
7.6.4 Power of Buyers [High]
7.6.5 Threat of Substitutes [Low]

8. Expert Opinion

8.1 Dr Katarzyna Nej-Wolosiak, Medical Science Lead, SOTIO
8.1.1 Issues in Prostate Cancer Treatment
8.1.2 Has Radical Prostatectomy Been Replaced?
8.1.3 Is Immunotherapy Still a Viable Option?
8.1.4 Current Challenges in Immunotherapy & Clinical Trial Design
8.1.5 Cost-effectiveness: Surgery vs Medical Treatments
8.1.6 How Cost-effective Is Immunotherapy?
8.1.7 DCVAC/ PCa: Mechanism of Action
8.1.8 DCVAC/ PCa: Side Effects & Immunotherapy
8.1.9 Advantages That Immunotherapy Offers
8.1.10 The Future of Immunotherapy: Shaping The Next Decade

9. Research Interviews

9.1 The Prostate Cancer Therapeutics Market, 2015-2025
9.2 The US Will Remain the Largest National Market from 2015 to 2025
9.3 Concluding Remarks

Conclusions

Glossary

List of Tables

Table 2.1 PSA Testing: Benefits and Limitations, 2015
Table 2.2 New Prostate Cancer Diagnostic Tests in Market, 2015
Table 2.3 Advantages and Disadvantages of Brachytherapy, 2015
Table 2.4 Advantages and Disadvantages of Radical Prostatectomy, 2015
Table 2.5 Advantages and Disadvantages of External Beam Radiation, 2015
Table 2.6 Advantages and Disadvantages of Cryotherapy, 2015
Table 2.7 Advantages and Disadvantages of HIFU, 2015
Table 3.1The Global Prostate Cancer Therapeutics Market: Revenue ($m), Market Share (%) by Segment, 2014
Table 3.2 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 3.3 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2015-2025
Table 4.1 The Prostate Cancer Drugs List: Key Brands, 2014
Table 4.2 The Prostate Cancer Drugs Market: Revenue ($m), Market Share (%) by Leading Drugs, 2014
Table 4.3 The Prostate Cancer Drugs Market Forecast by Leading Drugs, Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.4 Market Shares (%) of the Leading Prostate Cancer Drugs, 2014, 2019 and 2025
Table 4.5 Sanofi: Taxotere Revenue Forecast ($m), AGR (%), CAGR (%), 2014-2025
Table 4.6 Sanofi: Jevtana Global Sales Revenue ($m) in 2014 and 2013
Table 4.7 Sanofi: Jevtana Revenue Forecast ($m), AGR (%), CAGR (%), 2014-2025
Table 4.8 Casodex (AstraZeneca): Casodex Global Sales Revenue ($m) in 2014 and 2013
Table 4.9 AstraZeneca: Casodex Revenue Forecast ($m), AGR (%), CAGR (%), 2014-2025
Table 4.10 Lupron (AbbVie): Lupron Global Sales Revenue ($m) in 2014 and 2013
Table 4.11 AbbVie: Lupron Revenue Forecast ($m), AGR (%), CAGR (%), 2014-2025
Table 4.12 Zoladex (AstraZeneca): Zoladex Global Sales Revenue ($m) in 2014 and 2013
Table 4.13 Zoladex (AstraZeneca): Zoladex Revenue Forecast ($m), AGR (%), CAGR (%), 2014-2025
Table 4.14 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%), CAGR (%), 2014-2025
Table 4.15 Medivation/Astellas: Xtandi Revenue Forecast ($m), AGR (%), CAGR (%), 2014-2025
Table 4.16 Provenge (Dendreon): Provenge Revenue Forecast ($m), AGR (%), CAGR (%), 2014-2025
Table 4.17 Bayer: Xofigo Revenue Forecast ($m), AGR (%), CAGR (%), 2014-2025
Table 4.18 Other Prostate Cancer Drugs: Revenue Forecast ($m), AGR (%), CAGR (%), 2014-2025
Table 4.19 Key Drugs in Phase III Clinical Trials, 2015
Table 4.20 Negative Phase III Clinical Trials, 2015
Table 4.21 Key Drugs in Phase II Clinical Trials, 2015
Table 4.22 Key Drugs in Phase I Clinical Trials, 2015
Table 4.23 Johnson & Johnson: Revenue Shares (%) by Segment, 2014
Table 4.24 Johnson & Johnson: Historical Revenue ($bn), AGR (%), CAGR (%), 2009-2014
Table 4.25 Johnson & Johnson Pharmaceuticals: Revenue ($bn), and Revenue Shares (%) by Segment, 2014
Table 4.26 Johnson & Johnson Pharmaceuticals: Top 5 Best Selling Drugs
Table 4.27 Johnson & Johnson: Oncology Pharmaceuticals Segment: Revenue ($m) by Drug, 2013-2014
Table 4.28 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Company Revenue (%), 2011-2014
Table 4.29 AstraZeneca: Revenue ($bn), AGR (%), 2011-2014
Table 4.30 AstraZeneca: Revenue ($bn), Revenue Shares (%) by Segment, 2014
Table 4.31 AstraZeneca: R&D costs and percentage of sales, 2011-2014
Table 4.32 AstraZeneca: Oncology Drugs Revenue ($m), 2012-2014
Table 4.33 AstraZeneca Oncology: Investigational compounds, 2014
Table 4.34 Sanofi: Revenue ($bn), AGR (%), CAGR (%), 2010-2014
Table 4.35 Sanofi: Global Sales Revenue ($m) and Percentage Change (%) by Region, 2013-2014
Table 4.36 Sanofi: Sale Revenue ($bn) and Revenue Shares (%) by Segment, 2014
Table 4.37 Sanofi: Revenue ($m) and Revenue Share (%) by Sub-Segments, 2014
Table 4.38 Sanofi: Oncology Sales ($m) by Product, 2013-2014
Table 4.39 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2010-2014
Table 4.40 AbbVie: Revenue ($bn), AGR (%), CAGR (%), 2011-2014
Table 4.41 AbbVie Main Products: Revenue ($m) and Percentage Changes (%) from 2013 and 2014
Table 4.42 AbbVie: Humira Indications by Regions
Table 5.1 The Prostate Cancer Devices Market: Revenue ($m), Market Share (%) by Segment, 2014
Table 5.2 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2014-2025
Table 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m), Market Shares (%), 2014, 2019, 2025
Table 5.4 The Brachytherapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2025
Table 5.5 The Radical Prostatectomy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2025
Table 5.6 The External Beam Radiation Therapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2025
Table 5.7 The HIFU Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2025
Table 5.8 The Cryotherapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2025
Table 5.9 Varian Medical Systems: Revenue ($bn), AGR (%), CAGR (%), 2010-2014
Table 5.10 Varian Medical Systems: Revenue ($m) and Market Share (%), 2014
Table 5.11 Varian Medical Systems: Oncology Systems Revenue ($bn), Revenue Shares (%) by Segment, 2014
Table 5.12 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as Percentage of Revenue (%), 2011-2014
Table 5.13 Elekta: Revenue ($bn), AGR (%), CAGR (%) 2010-2014
Table 5.14 Theragenics: Revenue ($m), AGR (%), CAGR (%) 2008-2012
Table 5.15 Theragenics: Revenue ($m), Revenue Share (%) by Business Unit, 2012
Table 6.1 The Prostate Cancer Therapeutics Market: Revenue ($m) and Market Share (%) by Region, 2014
Table 6.2 The Leading Prostate Cancer Therapeutics National Market Forecasts: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 6.3 Market Shares (%) of the Leading Prostate Cancer Therapeutics National Markets, 2014, 2019 and 2025
Table 6.4 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 6.5 The European Prostate Cancer Therapeutics Markets: Revenue ($m), Market Share (%) by Country/Region, 2014
Table 6.6 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 6.7 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 6.8 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 6.9 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 6.10 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.11 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 6.12 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 6.13 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 6.14 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 6.15 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 6.16 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.17 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.18 The Mexican Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.19 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 7.1 SWOT Analysis of the Prostate Cancer Therapeutics Market, 2015-2025

List of Figures

Figure 1.1 The Global Over 65 Population: Forecast (millions, AGR%), 2013-2024
Figure 1.2 Prostate Cancer Therapeutics: Overview of Submarkets and Segments
Figure 2.1 Risk Factors Associated with Cancer Development
Figure 2.2 Global Proportion (%) of Newly diagnosed Cancer by Type (Excluding Non-Melanoma Skin Cancer), 2012
Figure 2.3 Risk Factors Associated with Prostate Cancer Development
Figure 2.4 Number of New Prostate Cancer Cases per 100 000 people of Different Ethnicities, 2012
Figure 2.5 Treatment Sequence for Prostate Cancer, 2015
Figure 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($m) by Segment, 2014
Figure 3.2 The Global Prostate Cancer Therapeutics Market: Market Share (%) by Segment, 2014
Figure 3.3 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 4.1 The Prostate Cancer Drugs Market: Revenue ($m) by Leading Drugs, 2014
Figure 4.2 The Prostate Cancer Drugs Market: Market Share (%) by Leading Drugs, 2014
Figure 4.3 The Prostate Cancer Drugs Market Forecast, Revenue ($m), AGR (%), 2014-2025
Figure 4.4 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drug, 2019
Figure 4.5 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drug, 2025
Figure 4.6 The Prostate Cancer Drugs Market: Sales Revenue ($m) by Region, 2025
Figure 4.7 Taxotere (Sanofi): Taxotere Revenue Forecast ($m), AGR (%) 2014-2025
Figure 4.8 Jevtana (Sanofi): Global Jevtana Sales Revenue ($m) and Percentage Change (%), 2014
Figure 4.9 Sanofi: Jevtana Revenue Forecast ($m), AGR (%) 2014-2025
Figure 4.10 Casodex (AstraZeneca): Casodex Global Sales Revenue ($m) in 2014 and 2013
Figure 4.11 AstraZeneca: Casodex Revenue Forecast ($m), AGR (%), 2014-2025
Figure 4.12 AbbVie: Lupron Sales Revenue ($m) and Percentage Change (%), 2014
Figure 4.13 AbbVie: Lupron Revenue Forecast ($m), AGR (%) 2014-2025
Figure 4.14 Zoladex (AstraZeneca): Zoladex Sales Revenue ($m) and Percentage Change (%) by Region, 2014
Figure 4.15 AstraZeneca: Zoladex Revenue Forecast ($m), AGR (%) 2014-2025
Figure 4.16 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%), 2014-2025
Figure 4.17 Medivation/Astellas: Xtandi Revenue Forecast ($m), AGR (%), 2014-2025
Figure 4.18 Provenge (Dendreon): Provenge Revenue Forecast ($m), AGR (%) 2014-2025
Figure 4.19 Bayer: Xofigo Revenue Forecast ($m), AGR (%), 2014-2025
Figure 4.20 Other Prostate Cancer Drugs: Revenue Forecast ($m), AGR (%), 2014-2025
Figure 4.21 Johnson & Johnson: Revenue Shares (%) by Segment, 2014
Figure 4.22 Johnson & Johnson: Historical Revenue ($bn), AGR (%), 2009-2014
Figure 4.23 Johnson & Johnson Pharmaceuticals: Revenue ($m) by Segment, 2014
Figure 4.24 Johnson & Johnson Pharmaceuticals: Revenue Shares (%) by Segment, 2014
Figure 4.25 Johnson & Johnson Pharmaceuticals: Revenue Shares (%) by Leading Drugs, 2014
Figure 4.26 Johnson & Johnson Oncology Pharmaceuticals Segment: Market Share (%) by Drug, 2014
Figure 4.27 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($ bn) and R&D Expenses as Percentage of Company Revenue (%), 2011-2014
Figure 4.28 AstraZeneca: Revenue ($bn), AGR (%), 2011-2014
Figure 4.29 AstraZeneca: Revenue ($bn) by Segment, 2014
Figure 4.30 AstraZeneca: Revenue Shares (%) by Segment, 2014
Figure 4.31 Astra Zeneca Pharmaceutical Pipeline: CVMD Compounds Currently Being Studied
Figure 4.32 AstraZeneca Pharmaceutical Pipeline: Infection, Neuroscience and Gastrointestinal Compounds Currently being Studied
Figure 4.33 AstraZeneca Pharmaceutical Pipeline: Infection, Neuroscience and Gastrointestinal Compounds Currently being Studied
Figure 4.34 AstraZeneca: R&D costs ($m) and Percentage of sales (%), 2011-2014
Figure 4.35 AstraZeneca: Oncology Drugs Revenue ($m), 2012-2014
Figure 4.36 AstraZeneca: Revenue share (%) of All Oncology Drugs, 2014
Figure 4.37 AstraZeneca: Collaborations, 2014
Figure 4.38 Sanofi: Historical Revenue ($bn), AGR (%), 2010-2014
Figure 4.39 Sanofi: Global Sales Revenue ($m) and Percentage Change (%) by Region, 2013-2014
Figure 4.40 Sanofi: Revenue ($m) by Segment, 2014
Figure 4.41 Sanofi: Revenue Share (%) by Segment, 2014
Figure 4.42 Sanofi: Pharmaceutical Sub-segment Revenue Shares (%), 2014
Figure 4.43 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Net Sales (%), 2010-2014
Figure 4.44 Sanofi: Major Compounds from Sanofi’s Oncology Pipeline, 2014
Figure 4.45 AbbVie: Revenue ($bn), AGR (%),2011-2014
Figure 4.46 AbbVie Main Products: Revenue ($m) Comparison, 2012-2014
Figure 4.47 AbbVie: Revenue Share (%) by Drug, 2014
Figure 4.48 AbbVie: R&D Segments, 2014
Figure 5.1 Segmentation of the Prostate Cancer Devices Marker, 2014
Figure 5.2 The Prostate Cancer Devices Market: Revenue ($m) by Segment, 2014
Figure 5.3 The Prostate Cancer Devices Market: Market Share (%) by Segment, 2014
Figure 5.4 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 5.5 The Prostate Cancer Devices Market Segments: Revenue ($m) Forecast, 2014, 2019, 2025
Figure 5.6 The Prostate Cancer Devices Market: Market Shares (%) by Leading Devices Submarkets, 2019
Figure 5.7 The Prostate Cancer Devices Market: Market Shares (%) by Leading Devices Submarkets, 2025
Figure 5.8 The Brachytherapy Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 5.9 The Radical Prostatectomy Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 5.10 The External Beam Radiation Therapy Market Forecast: Revenue ($m), AGR (%), 2015-2025
Figure 5.11 The HIFU Market Forecast: Revenue ($m), AGR (%), 2015-2025
Figure 5.12 The Cryotherapy Market Forecast: Revenue ($m), AGR (%), 2015-2025
Figure 5.13 Varian Medical Systems: Revenue ($bn), AGR (%), 2010-2014
Figure 5.14 Varian Medical Systems: Revenue ($m) by Segment, 2014
Figure 5.15 Varian Medical Systems: Revenue Share (%) by Segment, 2014
Figure 5.16 Varian Medical Systems: Oncology Systems Revenue ($bn) by Segment, 2014
Figure 5.17 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Segment, 2014
Figure 5.18 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Region, 2014
Figure 5.19 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as Percentage of Revenue (%), 2011-2014
Figure 5.20 Elekta: Historical Revenue ($bn), AGR (%), 2010-2014
Figure 5.21 Elekta: Historical Revenue by Region ($bn), 2013-2014
Figure 5.22 Theragenics: Revenue ($m), AGR (%), 2008-2012
Figure 5.23 Theragenics: Revenue Share (%) by Operation, 2012
Figure 5.24 Theragenics: Revenue ($m) by Business Unit, 2012
Figure 5.25 Theragenics: Revenue Share (%) by Business Unit, 2012
Figure 6.1 The Prostate Cancer Therapeutics Market: Revenue ($m) by Region, 2014
Figure 6.2 The Prostate Cancer Therapeutics Market: Market Share (%) by Region, 2014
Figure 6.3 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2019
Figure 6.4 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2025
Figure 6.5 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 6.6 The European Prostate Cancer Therapeutics Markets: Revenue ($m) by Country/Region, 2014
Figure 6.7 The European Prostate Cancer Therapeutics Markets: Market Share (%) by Country/Region, 2014
Figure 6.8 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 6.9 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-202 Figure
Figure 6.10 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR(%), 2014-20255
Figure 6.11 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 6.12 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 6.13 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 6.14 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 6.15 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%),2014-2025
Figure 6.16 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 6.17 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 6.18 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 6.19 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 6.20 The Mexican Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 6.21 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%),2014-2025
Figure 7.1 Porter’s Five Force Analysis of the Prostate Cancer Therapeutics Market, 2015-2025

掲載企業リスト

Companies Listed

Accord Healthcare Inc
Actavis Inc
Active Biotech/Ipsen
Advanced Medical Isotope Corporation (ADMB)
Advantagene
Advaxix Inc
Agensys
Algeta
AliosBioPharma
Amgen
Aragon Pharmaceuticals
Astellas
AstraZeneca
Bavarian Nordic
Bayer
Beckman Coulter (Danaher)
Bellicum Pharmaceuticals
Bostwick Laboratories
Bristol Myers Squibb
Computer Motion
Couagen AG
Cougar Biotechnology (Johnson & Johnson)
CP Medical (Theragenics)
CR Bard
Dendreon
Dendreon Corporation
EDAP TMS
Elekta
EMD Serono
Exelixis
Galt Medical (Theragenics)
GenomeDx Biosciences
Genomic Health
Hologic
Hospira
Immunocore limited
Intuitive Surgical
Iris International (Danaher)
Janssen
Johnson&Johnson
Kyowa Hakko Kirin
Macrogenics
MDxHealth
Medivation/Astellas Pharma
Merck & Co. (Merck)
Metabolon
Metamark Genetics
Millenium Pharmaceuticals
Mitomics
Mylan Pharmaceuticals
Myriad Genetics
NorthWest Biotherapeutics
Nucletron
OncoGenex
Oncura
Opko Health
Pharmacyclics
Progenics Pharmaceuticals
Radon Ltd (Elekta)
Regeneron
Roche
Sandoz
Sanofi
Seattle Genetics
Siemens Healthcare
SonaCare Medical
SOTIO
Steba Biotech
Sun Pharmaceuticals
Sython Pharmaceuticals
Takeda Pharmaceutical Company
Teva
Tokai Pharmaceuticals
Varian Medical Systems
Zydus Pharmaceuticals

Other Organisations Mentioned in this Report

American Cancer Society (ACS)
American Society of Clinical Oncology (ASCO)
American Society of Gene and Cellular Therapy (ASGCT)
Brazilian Industrial Biotech Association
Brigham Young University
Carnegie Institution for Science
Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia)
European Medicines Agency (EMA)
European Patent Office (EPO)
Georgetown University
Hannover Medical School
Kunshan RNAi Institute
Mary Crowley Cancer Research Centre
Max Planck Institute
MD Anderson Cancer Center
Ministry of Science and Technology (India)
National Institute for Health and Care Excellence (NICE) (UK)
National Institutes of Health (NIH) (US)
Ohio State University (OSU)
Pachyonychia Congenita Project
United States Food and Drug Administration (FDA)
University of Bayreuth
University of Calgary
University of Helsinki
University of Massachusetts Medical School
University of Oxford
University of Pittsburgh
US Department of Defense
Wellcome Trust
World Health Organization (WHO)

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。